Rakovina Therapeutics Inc. (TSXV:RKV), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, presented at the American Association of Cancer Research Annual Meeting. The AACR Annual Meeting, held from April 8th to 13th in New Orleans, is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine.
top of page
Recent PostsSee All
Revive will remain with the current protocol’s primary endpoint of proportion of patients meeting an endpoint of hospitalization or death..
Rakovina Therapeutics’ management will deliver a brief corporate overview and then be available for questions and discussions...
bottom of page